Protein Binding of Lipitor
Lipitor (atorvastatin), a statin for lowering cholesterol, binds extensively to plasma proteins—about 80-90% to albumin and other proteins.[1] This leaves only 10-20% free (unbound) drug available to exert pharmacological effects or cause toxicity in tissues.
How Protein Binding Affects Side Effects
High protein binding limits the free fraction of Lipitor that reaches target sites like muscles, liver, or kidneys. Side effects, such as myopathy (muscle pain/weakness) or rhabdomyolysis (severe muscle breakdown), arise mainly from the unbound drug interacting with muscle cells. Strong binding reduces free drug exposure, potentially lowering risk compared to drugs with low binding (e.g., <50%).[2][3]
Role of Drug Interactions
Protein binding influences side effects through displacement. Drugs competing for albumin sites—like gemfibrozil, cyclosporine, or clarithromycin—increase free Lipitor levels, elevating myopathy risk by 5-10 fold in some cases. FDA warnings highlight this for combination therapies.[4]
Patient Factors Altering Binding
Liver disease or low albumin (e.g., in malnutrition, nephrotic syndrome) reduces binding sites, raising free drug and side effect odds. Genetic variations in SLCO1B1 transporters, which handle unbound Lipitor uptake into liver/muscles, amplify myopathy independently of binding but interact with it.[5]
Comparison to Other Statins
| Statin | Protein Binding | Myopathy Risk Profile |
|--------|-----------------|-----------------------|
| Atorvastatin (Lipitor) | 80-90% | Moderate; interaction-sensitive |
| Simvastatin | ~95% | Higher baseline risk |
| Rosuvastatin | 88% | Lower muscle effects, more renal |
| Pravastatin | 50% | Least bound, fewer interactions |
Lipitor's binding sits mid-range, balancing efficacy and safety but requiring monitoring with interactors.[6]
Sources
[1] Lipitor Prescribing Information (Pfizer)
[2] Drug Protein Binding Review, Clin Pharmacokinet
[3] Statin Myopathy Mechanisms, NEJM
[4] FDA Drug Interactions Table
[5] SLCO1B1 and Statin Toxicity, Lancet
[6] Statin Comparison, Circulation